Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Cancer
Solid Tumors
Colorectal Cancer (CRC)
Gastric Cancer
Head and Neck Cancer
Lung Cancer
Renal Cell Carcinoma (RCC)
Bladder Cancer
UC (Urothelial Cancer)
Mesothelioma

Interventions

DRUG: INCB001158
DRUG: Pembrolizumab

Sponsor

Incyte Corporation